Skip to main content
Erschienen in: Digestive Diseases and Sciences 12/2012

01.12.2012 | Editorial

The Economic Burden of Inflammatory Bowel Disease: Clear Problem, Unclear Solution

verfasst von: Christian D. Stone

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Excerpt

Caring for and treating inflammatory bowel disease (IBD) patients may represent the most challenging aspect of a gastroenterologist’s clinical practice. One must properly assess the disease severity, make appropriate therapeutic recommendations, induce a sustained remission, and pay attention to many details during monitoring of care, all the while trying to keep up with a rapidly changing field that will soon introduce a host of new medications. As if this weren’t enough, we should also be mindful of the cost of IBD care. In our busy day-to-day practices, we likely do not appreciate how our clinical decision-making impacts the patient personally through their pocket book and affects the insurance system on which they depend. The article by Gunnarsson et al. [1] published in this issue of Digestive Diseases and Science highlights the economic burden of caring for Crohn’s disease (CD) and ulcerative colitis (UC) patients. The results are sobering. IBD care is expensive, and in this era of cost containment and health care reform, we as gastroenterologists need to prepare ourselves and take action to combat this growing problem. …
Literatur
1.
Zurück zum Zitat Gunnarsson C, Chen J, Rizzo JA, Ladapo JA. Lofland JH. The direct healthcare insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from United States National Survey. Dig Dis Sci. 2012 (Epub ahead of print). doi:10.1007/s10620-012-2289-y Gunnarsson C, Chen J, Rizzo JA, Ladapo JA. Lofland JH. The direct healthcare insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from United States National Survey. Dig Dis Sci. 2012 (Epub ahead of print). doi:10.​1007/​s10620-012-2289-y
2.
Zurück zum Zitat Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429.PubMedCrossRef Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429.PubMedCrossRef
3.
Zurück zum Zitat Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913.PubMedCrossRef Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913.PubMedCrossRef
4.
Zurück zum Zitat Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511.PubMedCrossRef Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511.PubMedCrossRef
5.
Zurück zum Zitat Everhart JE, editor. The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2008; NIH Publication No. 09-6443. Everhart JE, editor. The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2008; NIH Publication No. 09-6443.
6.
Zurück zum Zitat Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. 2008;14:6641–6647.PubMedCrossRef Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. 2008;14:6641–6647.PubMedCrossRef
7.
Zurück zum Zitat Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17:1603–1609.PubMedCrossRef Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17:1603–1609.PubMedCrossRef
8.
Zurück zum Zitat Cohen RD. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010;7:103–109.PubMedCrossRef Cohen RD. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010;7:103–109.PubMedCrossRef
9.
Zurück zum Zitat Saro C, da la Coba C, Casado MA, et al. Resource use in patients with Crohn’s disease treated with infliximab. Aliment Pharmacol Ther. 2007;26:1313–1323.PubMedCrossRef Saro C, da la Coba C, Casado MA, et al. Resource use in patients with Crohn’s disease treated with infliximab. Aliment Pharmacol Ther. 2007;26:1313–1323.PubMedCrossRef
10.
Zurück zum Zitat Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterol. 2005;128:862–869.CrossRef Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterol. 2005;128:862–869.CrossRef
11.
Zurück zum Zitat Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology. 2008;135:1493–1499.PubMedCrossRef Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology. 2008;135:1493–1499.PubMedCrossRef
12.
Zurück zum Zitat IBD Standards Group. Quality Care: Service Standards for the healthcare of people who have Inflammatory Bowel Disease (IBD). Oyster Healthcare Communications Ltd, 2009. IBD Standards Group. Quality Care: Service Standards for the healthcare of people who have Inflammatory Bowel Disease (IBD). Oyster Healthcare Communications Ltd, 2009.
Metadaten
Titel
The Economic Burden of Inflammatory Bowel Disease: Clear Problem, Unclear Solution
verfasst von
Christian D. Stone
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 12/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2417-8

Weitere Artikel der Ausgabe 12/2012

Digestive Diseases and Sciences 12/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.